key: cord-0996709-dpncpywx authors: Hariyanto, Timotius Ivan; Intan, Denny; Hananto, Joshua Edward; Harapan, Harapan; Kurniawan, Andree title: Vitamin D supplementation and Covid‐19 outcomes: A systematic review, meta‐analysis and meta‐regression date: 2021-06-27 journal: Rev Med Virol DOI: 10.1002/rmv.2269 sha: 19a07f779bb13dc5375111d71397d03d7102a240 doc_id: 996709 cord_uid: dpncpywx Vitamin D has many protective properties and potential role against acute lung injury. Low serum vitamin D is associated with high risk of pneumonia and development of acute respiratory distress syndrome. This study sought to analyse the efficacy of vitamin D in improving the outcomes of coronavirus disease 2019 (Covid‐19) patients. Using specific keywords, we comprehensively searched the potential articles on PubMed, Europe PMC and ClinicalTrials.gov database until 8th May 2021. All published studies on Covid‐19 and vitamin D were retrieved. Statistical analysis was conducted using Review Manager 5.4 software. A total of 11 studies with 22,265 Covid‐19 patients were included in the meta‐analysis. Our data suggested that vitamin D supplementation was associated with reduction in intensive care unit admission rate (OR 0.27; 95% CI: 0.09–0.76, p = 0.010, I (2) = 70%, random‐effect modelling); reduction of the need for mechanical ventilation (OR 0.34; 95% CI: 0.16–0.72, p = 0.005, I (2) = 61%, random‐effect modelling) and reduction of mortality from Covid‐19 (OR 0.37; 95% CI: 0.21–0.66, p < 0.001, I (2) = 50%, random‐effect modelling). Further analysis showed that the associations were influenced by age (p = 0.020). Our study suggests that vitamin D supplementation may offer beneficial effects on Covid‐19 outcomes. However, more randomized clinical trials are required to confirm this conclusion. varying from simple lower respiratory tract infections to acute respiratory distress syndrome (ARDS) and eventually may turn into multi-organ failure. 2, 3 Individuals with comorbidities such as obesity, diabetes, chronic respiratory disease, cardiovascular disease and other immunocompromising conditions are facing higher risks in developing the severe form of SARS-CoV-2 infections. [4] [5] [6] [7] [8] [9] For the past months, medical therapies to treat Covid-19 have been growing and evolving rapidly, ranging from supportive care, antivirals, anti-inflammatory agents and possible supplementations such as vitamin D. [10] [11] [12] [13] Several studies have shown that vitamin D has antiviral properties and potential roles against acute lung injury or ARDS, making large interest on vitamin D has rapidly emanated even in the early beginning of pandemic. 14, 15 Low vitamin D serum levels is associated with an increase in inflammatory cytokine levels and significant increase of risk to develop pneumonia and viral respiratory tract infections, which both contribute to the development of ARDS. [16] [17] [18] The goal of this study is to provide evidence whether or not vitamin D supplementation is associated with improved outcomes of Covid-19 based on the available studies. The protocol of this systematic review and meta-analysis study of the observational and clinical trial studies was registered in PROSPERO (CRD42021256117). Included articles were selected as potentially fulfilling the entry criteria: comply the PICO framework (P: Covid-19 patients; I: vitamin D supplementation in any form; C: a group of patients who did not receive vitamin D, only receive standard of care therapy or any other medications as control/placebo; O: intensive care unit [ICU] admission, the need for mechanical ventilation and mortality), cohort, case-control, cross-sectional and randomized or non-randomized clinical trial articles were included. All studies other than original research articles (review articles, letter to editor or correspondence), case-series or case report studies, studies reported other than in English language, studies focussing on populations below 18 years of age and pregnant women were excluded. with English-language restriction. Our searching strategy details are listed in Table 1 . Initial screening of titles and abstracts was conducted to identify eligible articles. Searches of potential articles were also done by analysing the list of references of eligible studies. The search strategy was presented in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram. The meta-analysis was performed using the Review Manager 3 | RESULTS The Jadad scale assessments suggested that one clinical trial study was graded high quality, while another study was graded moderate quality (Table 3) . Quality assessment of cohort and case-control studies using NOS scale and cross-sectional studies using JBI Critical Appraisal checklist indicated all included studies had a good quality (Table 4 and Table 5 ). Altogether, all studies were acceptable to be further analysed using meta-analysis. Six studies (n = 1516) reported the effect of vitamin D on the need for mechanical ventilation outcome. The pooled analysis suggested that vitamin D supplementation was associated with reduction of the (4) withdrawals and drop-outs: numbers and reasons are described, 1 point; not described, 0 point. The Jadad scale score ranges from 1 to 7; higher score indicates better RCT quality. If a study had a modified Jadad score >4 points, it was considered to be of high quality; if the score was 3-4 points, it was moderate quality; and if the score was <3 points, it was low quality. HARIYANTO ET AL. Ten studies (n = 2223) reported on mortality. The pooled estimate showed that vitamin D supplementation was associated with reduction of mortality from Covid-19 (OR 0.37; 95% CI: 0.21-0.66, p < 0.001, I 2 = 50%, random-effect modelling; Figure 2c ). Our meta-regression suggested the association between vitamin D supplementation and mortality was affected by age (p = 0.027; Note: ** means the score is 2, *** means the score is 3. All the scores were sum up to get the final score and to conclude the quality of included studies. Jevalikar G et al. 27 granulocyte-macrophage colony stimulating factor but stimulates the immunosuppressive prostaglandin E2 production by the macrophages. 41 Importantly, vitamin D deficiency impairs macrophage maturation. 41 Several studies have shown that the risk of Covid-19 increases in people with vitamin D deficiencies; furthermore, lower concentration also contributes to the development of ARDS. 46, 47 Aside from that, vitamin D has also been known to induce the pro- 53 The VDR and calcitriol also prevent lung, liver and kidney fibrosis through the downregulation of RAS and the inhibition of NF-κB and wnt/β-catenin. 54, 55 F I G U R E 5 The role of vitamin D in suppressing the nuclear factor kappa B (NF-κB) signalling pathway (a) and the proposed potential therapeutic effect of vitamin D for COVID-19 and induced acute respiratory distress syndrome (b) A cohort study that investigates the influence of genetic variation in vitamin D pathway found that three SNP in VDR (rs4334089, rs11568820 and rs7970314) are associated with increased risk of upper respiratory tract infection. 56 A systematic review and metaanalysis study which evaluates the association between VDR polymorphism and severe Respiratory Syncytial Virus (RSV)-bronchiolitis supports the association between FokI polymorphism and severe RSV infection. This study also examines the role of six VDR polymorphisms (Cdx, A1012G, FokI, BsmI, ApaI and TaqI) on infection susceptibility to enveloped virus found that a polymorphism at locus rs2228570 (FokI) is associated with viral infections. 57 The TT genotype and T allele were reported to be risk factors for infections with enveloped viruses, including RSV. 58, 59 Being an enveloped virus, it may be the same case for SARS-CoV-2. The mechanism that explains the association of FokI polymorphism with increased viral infection is that the FokI polymorphism creates a shorter VDR proteins that causes higher rate of transcription driven by the NF-κB, increased IL-12 and higher lymphocyte proliferation. 56 Therefore, supplementation with vitamin D may help in ameliorating those potentially negative effects from viral infection. All of these properties and roles might explain the benefit of vitamin D on the outcomes of Covid-19. This study has some limitations. Significant heterogeneities were identified on most of the outcomes of interests included in this study. This was probably caused by the difference in the given vitamin D doses and co-administered medications with vitamin D as Covid-19 treatment. Importantly, we have made rigorous efforts to ensure that only sound studies were included, and several pre-print studies were included to minimize the risk of publication bias. Our meta-analysis indicates that vitamin D supplementation had an association with favourable outcomes of Covid-19, compromising reduction in the rate of ICU admission, reduction in mechanical ventilation usage and reduction of mortality rate from Covid-19. This study suggests that vitamin D might be a potential therapeutic agent for the management of Covid-19 to give better outcomes for the patients. However, more randomized clinical trial studies are still necessary and should be done to confirming the results of our study. Finally, vitamin D might be considered as an essential drug for future Covid-19 therapy models. Coronavirus disease (COVID-19): situation report Anosmia/Hyposmia is a good predictor of coronavirus disease 2019 (COVID-19) infection: a meta-analysis Coronavirus disease 2019 and cardiovascular system: a narrative review Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: a systematic review, meta-analysis, and meta-regression Human immunodeficiency virus and mortality from coronavirus disease 2019: a systematic review and meta-analysis Dementia is associated with severe coronavirus disease 2019 (COVID-19) infection COVID-19 and comorbidities: a systematic review and metaanalysis Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression Efficacy and safety of tocilizumab for coronavirus disease 2019 (Covid-19) patients: a systematic review and meta-analysis Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis Ivermectin and outcomes from Covid-19 pneumonia: a systematic review and meta-analysis of randomized clinical trial studies Vitamin D and Covid-19: an update on evidence and potential therapeutic implications COVID-19 and vitamin D-Is there a link and an opportunity for intervention? Vitamin D deficiency contributes directly to the acute respiratory distress syndrome Evidence for possible association of vitamin D status with cytokine storm and unregulated inflammation in COVID-19 patients Does vitamin D deficiency increase the severity of COVID-19 Perioperative antibiotics to prevent acute endophthalmitis after ophthalmic surgery: a systematic review and meta-analysis Operating characteristics of a rank correlation test for publication bias Vitamin D supplementation associated to better survival in hospitalized frail elderly COVID-19 patients: the GERIA-COVID quasi-experimental study Vitamin D and survival in COVID-19 patients: a quasiexperimental study Mortality in an Italian nursing home during COVID-19 pandemic: correlation with gender, age, ADL, vitamin D supplementation, and limitations of the diagnostic tests Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study Effectiveness of in-hospital cholecalciferol use on clinical outcomes in comorbid COVID-19 patients: a hypothesis-generating study Vitamin D status in hospitalized patients with SARS-CoV-2 infection Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19 High-dose cholecalciferol booster therapy is associated with a reduced risk of mortality in patients with COVID-19: a cross-sectional multi-centre observational study Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19) The association of 25 (OH) vitamin D levels and severity and outcome of COVID-19: a cross-sectional study Publication bias in meta-analysis: its causes and consequences Adjusting for publication bias in the presence of heterogeneity Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: a systematic review and meta-analysis Functional exhaustion of antiviral lymphocytes in COVID-19 patients Covid-19: time for a paradigm change Pathological findings of COVID-19 associated with acute respiratory distress syndrome Dysregulation of immune response in patients with coronavirus 2019 (COVID-19 Hassanzadeh G. COVID-19 and multiorgan failure: a narrative review on potential mechanisms Vitamin D3 as potential treatment adjuncts for COVID-19 Cathelicidins: immunomodulatory antimicrobials. Vaccines (Basel) A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 Effect of vitamin D and β-sitosterol on immune function of macrophages Impact of the vitamin D deficiency on COVID-19 infection and mortality in Asian countries Vitamin D deficiency among patients with COVID-19: case series and recent literature review Reply to Jakovac: COVID-19, vitamin D, and type I interferon Vitamin D and COVID-19 in an immunocompromised patient with multiple comorbidities-A Case Report Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers Kurniawan A. The use of ACE inhibitor/ARB in SARS-CoV-2 patients: a comprehensive narrative review A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: implications for a potential treatment for COVID-19 Beyond the RAAS: dissecting the antifibrotic effects of vitamin D analogues NF-κB signaling in inflammation Vitamin D receptor genotype influences risk of upper respiratory infection Vitamin D receptor (VDR) polymorphisms and severe RSV bronchiolitis: a systematic review and meta-analysis Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection Vitamin D Receptor polymorphisms and risk of enveloped virus infection: a meta-analysis Vitamin D supplementation and Covid-19 outcomes: A systematic review, meta-analysis and meta-regression None. The authors declare that there is no conflict of interest. Data analysed in this study were a re-analysis of existing data, which are openly available at locations cited in the reference section. https://orcid.org/0000-0002-1748-9776Harapan Harapan https://orcid.org/0000-0001-7630-8413Andree Kurniawan https://orcid.org/0000-0002-5219-9029